266 related articles for article (PubMed ID: 30383490)
1. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
3. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
[TBL] [Abstract][Full Text] [Related]
4. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
6. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome.
Tessaris D; Matarazzo P; Lala R; Defabianis P
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):333-6. PubMed ID: 26565547
[TBL] [Abstract][Full Text] [Related]
7. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
8. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
10. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.
Thomsen MD; Rejnmark L
Calcif Tissue Int; 2014 Apr; 94(4):384-95. PubMed ID: 24390518
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
12. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
[TBL] [Abstract][Full Text] [Related]
14. Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.
Hagelstein-Rotman M; Appelman-Dijkstra NM; Boyce AM; Chapurlat R; Dur NBJ; Gensburger D; Majoor BCJ; van de Sande MAJ; Dijkstra PDS
Calcif Tissue Int; 2022 Mar; 110(3):334-340. PubMed ID: 34854944
[TBL] [Abstract][Full Text] [Related]
15. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India.
Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N
Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism in McCune-Albright Syndrome and Role of Bone Scan in Management of Fibrous Dysplasia: An Unusual Case Scenario with Review of Literature.
Kumar N; Kheruka SC; Singh RK; Ravina M; Dutta D; Gambhir S
Indian J Nucl Med; 2017; 32(1):25-29. PubMed ID: 28242980
[TBL] [Abstract][Full Text] [Related]
17. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
[TBL] [Abstract][Full Text] [Related]
18. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.
Akintoye SO; Boyce AM; Collins MT
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):e149-55. PubMed ID: 23953425
[TBL] [Abstract][Full Text] [Related]
19. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.
Nadella S; Mupparapu M; Akintoye SO
Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165
[TBL] [Abstract][Full Text] [Related]
20. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]